

Corporate Fact Sheet

Company Overview

Bilcare Research (BSE: BIL, CODE: 526853) is one of the world's leading providers of integrated solutions to the global pharmaceutical industry. Our sole focus is to fulfill the unmet needs of the pharmaceutical industry in the areas of packaging, clinical trial supplies and brand protection and management. We endeavor to enhance people's lives by helping pharmaceutical companies accelerate drug development lifecycles and combat counterfeit drugs. With a strong R&D and manufacturing base, we develop end-to-end, innovative and cost effective solutions for the entire pharmaceutical value chain.

Our Businesses

- Pharmed Packaging Innovations (PPI)
- Global Clinical Supplies (GCS)
- Bilcare Technologies

Global Footprint

United Kingdom

- Clinical trial services facility
- MHRA approved site

USA

- Clinical trial services facility
- 14 acre FDA & DEA approved site
- Films & foils secondary production

India

- Films & foils production
- Clinical trial services facility – 1st in Asia
- Research facilities – DSIR approved
- Award winning – OPPI "Best Vendor" consecutively

Singapore

- Films production & research centre
- Clinical trial services facility
- Pioneer Status from Singapore Govt.

Bilcare's Competitive Edge

- Leading provider of research-driven packaging solutions
- Comprehensive and innovative product portfolio
- State-of-the-art, award winning research and manufacturing facilities
- Global footprint with operations in Singapore, U.S., UK, Germany and India
- A reputation for excellence in quality and customer service
- Unrivalled performance servicing the requirements of the entire pharmaceutical value chain

Customers

Bilcare Research caters to over 500 pharmaceutical companies worldwide, including the following, among others:



Strategy

Bilcare Research maintains a defined focus on meeting the challenges faced by the global pharmaceutical industry. We will continue to drive innovation in developing packaging solutions to address the stagnating sales of existing brands in the market place and bolstering the drug discovery pipeline through clinical service solutions.

Board of Directors as on September 30, 2009

- | | |
|-------------------------|----------------------|
| • Mohan Bhandari | • Dr. Arthur Carty |
| • Dr. Praful Naik | • Rajendra Tapadia |
| • Dr. Kalyani Gandhi | • Dr. Bhojraj Suresh |
| • Dr. Volker Huelck | • Dr. R V Chaudhari |
| • Chandra Prakash Jaggi | |

Financial Performance

The company registered a growth of 40.9% in its consolidated net profit for the year ended March 2010, at Rs.116.87 crore as against Rs. 82.94 crore for the corresponding previous year. Consolidated sales for the year ended March 31, 2010 stood at Rs. 1047.48 crore as against Rs. 856.02 crore of previous year, recording a growth of 22.36%.

Research & Operations	Regional Offices	Representative Offices
<p>Bilcare Singapore Pte. Ltd. 52 Changi South Street 1 Singapore 486161 direct-sg@bilcare.com</p> <p>Bilcare Limited 1028 Shiroli, Rajgurunagar Pune 410505 direct-in@bilcare.com</p> <p>Bilcare Inc 300 Kimberton Road Phoenixville PA 19460 direct-us@bilcare.com</p> <p>Bilcare GCS (Europe) Ltd Waller House, Elvicta Business Park, Crickhowell Powys NP8 1DF UK. direct-europe@bilcare.com</p>	<p>Bilcare Room 701, No.89 Xing Tai Road Baiyu District, Guangzhou direct-ch@bilcare.com</p> <p>Bilcare GmbH Industriepark Höchst 65926 Frankfurt Main direct-eu@bilcare.com</p> <p>Bilcare Marketing America Latina Ltda. Alameda Campinas 834 - Apto 111 Jardim Paulista - CEP:01404-001 Sao Paulo direct-br@bilcare.com</p> <p>Bilcare 5-Eurong Street, Wahroonga, NSW 2076 Sydney direct-au@bilcare.com</p>	<p>Argentina Bangladesh Chile Colombia Czech Republic Egypt France Indonesia Iran Israel Jordan Korea Malaysia Mexico Pakistan Saudi Arabia South Africa Spain Taiwan Thailand Turkey Venezuela Vietnam</p>

© 2009, Bilcare Limited. All Rights Reserved.

FORWARD LOOKING STATEMENTS: This fact sheet is neither an offer nor solicitation to buy or sell any securities mentioned and is for educational purposes only. While it is believed all sources of information are factual and reliable, in no way is it represented or guaranteed that the description or statements herein are accurate and complete. The reader should verify all claims and do his/her/their own due diligence before investing in any securities mentioned. Any forward-looking statements involve risks and uncertainties. Bilcare Research does not undertake any obligation to update any forward looking statement, except as required under applicable law. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent of Bilcare Limited. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.